Zhang Jilu, Mai Sunny, Chen Hui-Ming, Kang Kyeongah, Li Xian Chang, Chen Shu-Hsia, Pan Ping-Ying
Department of Oncological Sciences, Icahn School of Medicine, Mount Sinai, New York, New York, USA.
Immunobiology & Transplant Science Center, Houston Methodist Hospital, Texas Medical Center, Houston, Texas, USA.
J Leukoc Biol. 2017 Aug;102(2):351-360. doi: 10.1189/jlb.5MR1216-534R. Epub 2017 Mar 28.
Myeloid-derived suppressor cells (MDSCs), a population of immature myeloid cells expanded and accumulated in tumor-bearing mice and in patients with cancer, have been shown to mediate immune suppression and to promote tumor progression, thereby, posing a major hurdle to the success of immune-activating cancer therapies. MDSCs, like their healthy counterparts, such as monocytes/macrophages and granulocytes, express an array of costimulatory and coinhibitory molecules as well as myeloid activators and inhibitory receptors, such as leukocyte immunoglobulin-like receptors (LILR) A and B. This review summarizes current findings on the LILR family members in various diseases, their potential roles in the pathogenesis, and possible strategies to revert or enhance the suppressive function of MDSCs for the benefit of patients by targeting LILRs.
髓源性抑制细胞（MDSCs）是一群在荷瘤小鼠和癌症患者体内扩增并积累的未成熟髓细胞，已被证明可介导免疫抑制并促进肿瘤进展，因此，这对免疫激活癌症治疗的成功构成了主要障碍。MDSCs与它们的健康对应物，如单核细胞/巨噬细胞和粒细胞一样，表达一系列共刺激和共抑制分子以及髓系激活剂和抑制性受体，如白细胞免疫球蛋白样受体（LILR）A和B。本综述总结了目前关于LILR家族成员在各种疾病中的研究结果、它们在发病机制中的潜在作用，以及通过靶向LILRs恢复或增强MDSCs抑制功能以造福患者的可能策略。
